Last reviewed · How we verify
heparin + clopidogrel + aspirin
This triple antiplatelet and anticoagulant combination inhibits blood clot formation through multiple pathways: heparin blocks thrombin and factor Xa, while clopidogrel and aspirin inhibit platelet aggregation.
This triple antiplatelet and anticoagulant combination inhibits blood clot formation through multiple pathways: heparin blocks thrombin and factor Xa, while clopidogrel and aspirin inhibit platelet aggregation. Used for Acute coronary syndrome, Prevention of thrombotic events in high-risk cardiovascular patients.
At a glance
| Generic name | heparin + clopidogrel + aspirin |
|---|---|
| Also known as | héparine Choay Plavix Kardégic |
| Sponsor | Centre Hospitalier de PAU |
| Drug class | Antiplatelet and anticoagulant combination |
| Target | Thrombin, Factor Xa, Cyclooxygenase, P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin is an anticoagulant that potentiates antithrombin III to inactivate thrombin and factor Xa, preventing fibrin formation. Aspirin irreversibly inhibits cyclooxygenase to reduce thromboxane A2 and platelet aggregation. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-mediated platelet activation. Together, these agents provide synergistic antithrombotic effects through complementary mechanisms.
Approved indications
- Acute coronary syndrome
- Prevention of thrombotic events in high-risk cardiovascular patients
Common side effects
- Bleeding
- Thrombocytopenia
- Gastrointestinal hemorrhage
- Intracranial hemorrhage
Key clinical trials
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
- To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction. (PHASE3)
- Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI) (PHASE2)
- A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke (PHASE2)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Endovascular Acute Stroke Intervention - Tandem OCclusion Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- heparin + clopidogrel + aspirin CI brief — competitive landscape report
- heparin + clopidogrel + aspirin updates RSS · CI watch RSS
- Centre Hospitalier de PAU portfolio CI